Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A First-In-Human, Clinical Study Investigating FT500 in Combination with Checkpoint Inhibitor Therapy for the Treatment of Advanced Solid Tumors

Trial Profile

A First-In-Human, Clinical Study Investigating FT500 in Combination with Checkpoint Inhibitor Therapy for the Treatment of Advanced Solid Tumors

Planning
Phase of Trial: Phase I

Latest Information Update: 30 Nov 2018

At a glance

  • Drugs Atezolizumab (Primary) ; FT 500 (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Fate Therapeutics
  • Most Recent Events

    • 30 Nov 2018 According to a FateTherapeutics media release, the U.S. Food and Drug Administration has allowed the companys IND application for FT500.This clinical trial is expected to be the first-ever clinical investigation in the U.S. of an iPSC-derived cell product.
    • 14 Nov 2018 New trial record
    • 01 Nov 2018 According to a Fate Therapeutics media release, in July, the company submitted an investigational new drug (IND) application to the U.S. FDA for FT500.In response to a request by the FDA, the Company is conducting additional adventitious agents testing of the master iPSC bank used for the production of FT500, and intends to submit these test results to the FDA during the fourth quarter of 2018. Upon FDA allowance of the IND, the company expects to begin this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top